5[5]Baker DE.Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.Rev Gastroenterol Disord,2003,3(2):93-109.
6[6]Lin C-C, Luu K, Lourenco D,et al.Viramidine, a prodrug of ribavirin, demonstrated superior liver-targeting properties and much improved toxicity profile in cynomolgus monkey studies.Hepatology,2001,34(Suppl):453A.
7[7]Afdhal N,Flamm S,Imperial JC,et al.Analyses of 40 KDA peginterferon alf α-2a in combination with ribavirin, mycophenolate mofetil, amantadine or amantadine plus ribavirin in patients that relapsed or did not respond to rebetron therapy: a report of two randomized, multicenter, efficacy and safety studies.Hepatology,2001,34(Suppl):243A.
8[8]Lurie Y,Pakula R,Malnick S,et al.Efficacy and safety of the combination of histamine dihydrochloride and interferon alph α-2b in a phase II trial in naive patients with chronic hepatitis C. Hepatology,2001,34(Suppl): 350A.
9[9]McHutchison JG,Pockros P,Nyberg LM, et al.A dose escalation study of ISIS 14803,an antisense inhibitor of HCV, in chronichepatitis C patients.Hepatology ,2001,34(Suppl):350A.
10[10]Usman N,Blatt LM. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics.J Clin Invest,2000,106(10):1197-1202.
4Liang JT,Rustgi V,Galun E.HCV RNA in patients with chronic hepatitis C treated with interferon-α[J].J Med Viral,1993,40(1):69-75.
5Hitzler WE,Runkel S.Screening of blood donations by hepatitis C virus polymerase chain reaction (HCV-PCR) improves safety of blood products by window period reduction[J].Clin Lab,2001,47(5-6):219-222.
6Hagiwara H,Hayashi N,Muta E,et al.Quantitation of HCV RNA in serum of asymptomatic blood donors and patients with types C chronic liver disease[J].Hepatology,1998,17(8):545-550.
7Poynard T,Bedossa P,Opolon P,et al.Natural history of liver fibrosis progression in patients with chronic hepatitis C [J].Lancet,1997,349:825-832.
